AstraZeneca (AZN.L) rises after $2 billion equity investment in Summit Therapeutics
AstraZeneca said it will invest $2 billion in Summit Therapeutics via convertible preferred shares at a conversion price of $18.36 per share, an 18.6% premium to its last close; the stock was up 1.5% at £126.8.